Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) EBITDA (2021 - 2025)

Historic EBITDA for HeartSciences (HSCS) over the last 5 years, with Q4 2025 value amounting to -$2.1 million.

  • HeartSciences' EBITDA fell 445.18% to -$2.1 million in Q4 2025 from the same period last year, while for Oct 2025 it was -$8.2 million, marking a year-over-year decrease of 1036.08%. This contributed to the annual value of -$8.4 million for FY2025, which is 3245.92% down from last year.
  • HeartSciences' EBITDA amounted to -$2.1 million in Q4 2025, which was down 445.18% from -$1.9 million recorded in Q3 2025.
  • In the past 5 years, HeartSciences' EBITDA registered a high of -$674446.0 during Q3 2021, and its lowest value of -$2.4 million during Q1 2025.
  • In the last 5 years, HeartSciences' EBITDA had a median value of -$1.7 million in 2022 and averaged -$1.6 million.
  • In the last 5 years, HeartSciences' EBITDA crashed by 11204.03% in 2022 and then surged by 1917.02% in 2023.
  • Over the past 5 years, HeartSciences' EBITDA (Quarter) stood at -$956856.0 in 2021, then crashed by 85.49% to -$1.8 million in 2022, then increased by 11.55% to -$1.6 million in 2023, then dropped by 26.44% to -$2.0 million in 2024, then fell by 4.45% to -$2.1 million in 2025.
  • Its EBITDA was -$2.1 million in Q4 2025, compared to -$1.9 million in Q3 2025 and -$1.9 million in Q2 2025.